Ginkgo Bioworks DNA Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$76.06M+16.4% | -$80.75M+24.9% | -$80.76M-43.2% | -$60.3M+72.2% | -$90.96M+45.2% | ||
| $12.8M-13.6% | $13.66M-12.7% | $14.17M-17.5% | $16.34M-5.7% | $14.82M+15.2% | ||
| $15.85M-8.8% | $21.03M+2.3% | $17.84M+28.8% | $25.29M-31.9% | $17.39M-57.4% | ||
| —— | -$341K-45.7% | -$341K-45.7% | -$341K-45.7% | -$341K-45.7% | ||
| $242K-63.7% | $1.82M— | -$757K-115% | —— | $667K-90.1% | ||
| -$11.6M-231% | —— | $22.12M+153% | -$13.99M-199,814% | $8.87M-18.4% | ||
| -$94K-156% | -$334K-128% | —— | —— | $167K-76.4% | ||
| -$758K— | $7M+7,196% | $0— | $5.16M— | $0-100% | ||
| -$185K-24.2% | -$453K+20.4% | -$1.57M— | $0+100% | -$149K-134% | ||
| -$2.61M+80.2% | -$5.18M-499% | -$3.53M+93.0% | -$10.49M+25.6% | -$13.19M-353% | ||
| $7.11M-3.6% | $7.63M+2.1% | $7.58M+0.5% | $7.49M+0.7% | $7.38M+30.9% | ||
| -$5M-4.3% | -$9.14M-161% | -$7.16M+4.8% | -$6.85M— | -$4.79M-16.9% | ||
| -$46.69M+9.4% | -$47.68M-12.4% | -$31.61M+69.5% | -$40.25M+52.3% | -$51.52M+42.3% | ||
| $1.93M-74.6% | $5K-100.0% | $0-100% | $38K-99.9% | $7.62M+13.6% | ||
| $83.16M-56.5% | $16.79M— | $81.71M— | $128.95M— | $191.18M— | ||
| $108.18M— | $25.9M+756% | -$64.96M-1,744% | $64.96M— | $0— | ||
| -$48K+60.0% | —— | -$249K+28.2% | -$142K+25.7% | -$120K— | ||
| $23.13M+112% | —— | -$72.82M-614% | -$63.89M-138% | -$198.68M-1,541% | ||
| $19K-90.8% | $25K-87.7% | $24K-88.0% | $98K-51.0% | $207K-29.6% | ||
| —— | $0— | $0— | $0— | $0— | ||
| -$19K+90.8% | $8.14M+4,111% | $9.94M+2,237% | -$98K+56.6% | -$207K+75.5% | ||
| -$129K-274% | —— | $93K+366% | $186K+1,263% | $74K+147% | ||
| -$23.7M+90.5% | —— | -$94.39M+17.3% | -$104.05M+6.7% | -$250.34M-145% | ||
| $0-100% | —— | —— | $2.93M+191% | $1.3M+40.6% | ||
| -$253K+97.1% | —— | —— | —— | -$8.77M— | ||
| -$1.21M+67.1% | —— | —— | -$265K+96.1% | -$3.69M-45.2% | ||
| -$5M-4.3% | -$9.14M-161% | -$7.16M+4.8% | -$6.85M— | -$4.79M-16.9% | ||
| -$11.6M-231% | —— | $22.12M+153% | -$13.99M-199,814% | $8.87M-18.4% | ||
| -$758K— | $7M+7,196% | $0— | $5.16M— | $0-100% | ||
| -$5.93M-1,121% | $5.18M+178% | —— | $1.69M+375% | $581K+150% | ||
| $0+100% | —— | —— | -$139K+99.0% | -$3.68M— | ||
| —— | $0+100% | $0+100% | $0+100% | $0+100% | ||
| $7.11M-3.6% | $7.63M+2.1% | $7.58M+0.5% | $7.49M+0.7% | $7.38M+30.9% | ||
| -$185K-24.2% | -$453K+20.4% | -$1.57M— | $0+100% | -$149K-134% | ||
| -$48K+60.0% | —— | -$249K+28.2% | -$142K+25.7% | -$120K— | ||
| —— | $0— | $0— | $0— | $0— | ||
| $108.18M— | $85.88M— | —— | —— | $0— | ||
| $19K-90.8% | $25K-87.7% | $24K-88.0% | $98K-51.0% | $207K-29.6% | ||
| -$6.76M-27.9% | —— | -$400K-40,100% | —— | -$5.29M— | ||
| -$2.61M+80.2% | -$5.18M-499% | -$3.53M+93.0% | -$10.49M+25.6% | -$13.19M-353% | ||
| -$5M-4.3% | -$9.14M-161% | -$7.16M+4.8% | -$6.85M— | -$4.79M-16.9% | ||
| -$48.62M+17.8% | -$47.68M+15.1% | -$31.61M+73.3% | -$40.29M+63.8% | -$59.14M+38.4% | ||
| -$48.62M+17.8% | -$47.68M+15.1% | -$31.61M+73.3% | -$40.29M+63.8% | -$59.14M+38.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Ginkgo Bioworks generate?
- Ginkgo Bioworks (DNA) generated -$166.2M in operating cash flow over the trailing twelve months.
- What is Ginkgo Bioworks's free cash flow?
- After $2.0M of capital expenditures, Ginkgo Bioworks's free cash flow was -$168.2M over the trailing twelve months, up 51.3% year over year.
- Where does Ginkgo Bioworks's cash flow data come from?
- Every line is extracted from Ginkgo Bioworks's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
